Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX-471 in Patients With NCAM Positive Tumors
NCT07684170Phase 2Not yet recruiting
- Sponsor
- Compass Therapeutics, Inc.
- Start
- Sep 2026
- Primary completion
- Sep 2028
01
Overview
A Phase 2 trial of ctx-471 in Neuroendocrine neoplasm (NEN), sponsored by Compass Therapeutics, Inc.. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ctx-471
03
Conditions
Neuroendocrine neoplasm (NEN)
Beyond the preview
Go deeper on NCT07684170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07684170.